The effect of adipose tissue on inductive adipogenesis within Matrigel (BD Biosciences) was assessed by using a murine chamber model containing a vascular pedicle. Three-chamber configurations that varied in the access to an adipose tissue source were used, including sealed-and open-chamber groups that had no access and limited access, respectively, to the surrounding adipose tissue, and a sealed-chamber group in which adipose tissue was placed as an autograft. All groups showed neovascularization, but varied in the amount of adipogenesis seen in direct relation to their access to preexisting adipose tissue: open chambers showed strong adipogenesis, whereas the sealed chambers had little or no adipose tissue; adipogenesis was restored in the autograft chamber group that contained 2-to 5-mg fat autografts. These showed significantly more adipogenesis than the sealed chambers with no autograft ( p < 0.01). Autografts with 1 mg of fat were capable of producing adipogenesis but did so less consistently than the larger autografts. These findings have important implications for adipose tissue engineering strategies and for understanding de novo production of adipose tissue.
INTRODUCTION
A DIPOSE TISSUE GRAFTS are widely used in reconstructive and cosmetic surgery. For reconstruction of large defects after cancer or trauma, such as breast reconstruction after mastectomy, larger volumes of adipose tissue are required than can be provided by simple fat grafting. There has, therefore, recently been increasing interest in the possibility of creating new fat tissue by tissue engineering techniques. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Kawaguchi et al. 1 demonstrated that if Matrigel, a basement membrane-rich extracellular matrix derived from a mouse sarcoma, 12 is injected subcutaneously in mice with the proangiogenic growth factor basic fibroblast growth factor (bFGF), the gel will be replaced by mature adipose tissue over 3-10 weeks. If bFGF is not added, adipose tissue does not form; as a result, the authors suggested a critical role for angiogenesis in the process of adipose tissue formation. Subsequent studies have suggested that the mechanism for the new tissue formation is inductive, with the surrounding tissues having an important role in providing stem cells for the de novo adipogenesis. 13 We recently described an in vivo murine model of tissue engineering for vascularized adipose tissue. 2 This involves a subcutaneously implanted 5-mm-long, 0.05-mL-volume silicone chamber that ensleeves the superficial epigastric vessels. This induces spontaneous angiogenesis and adipogenesis, and the resulting product is based on a vascular pedicle.
The development of a human equivalent to Matrigel for adipose tissue engineering requires a better understanding of the mechanisms involved in such inductive adipose tissue engineering, particularly the influence of neovascularization and the role of the surrounding tissue. To date, the relative roles of the surrounding tissue and neovascularization in inductive adipogenesis remain unclear. Our murine ''chamber model,'' comprising a perivascular silicone tubing chamber and modified from the method first described by Cronin et al.,
2 is ideal for investigating these factors because it provides an isolated environment for such studies. Silicone was retained as the chamber material for several reasons, including its proven use in the existing model, its ready availability, its pliable handling, its minimal tissue reaction, and its established use in other animal models for purposes such as nerve entubulation repair. 14 
METHODS

Chamber insertion and subcutaneous Matrigel plugs
Tissue engineering chambers were inserted bilaterally in a method modified from Cronin et al., 2 as shown in Fig. 1 . Eight-week-old male C57/Bl6 mice were anesthetized with 4% intraperitoneal chloral hydrate (Merial, Paramatta, Australia) and given 5 mg/kg of Carprofen (Pfizer, West Ryde, Australia) subcutaneously for analgesia. The groin regions were depilated. A longitudinal incision was made in the groin, and the superficial epigastric vessels were isolated, then stripped meticulously of adipose tissue for 7-8 mm and wrapped in a 5-mm length of 3.35-mm-internal-diameter silicone tubing (Dow Corning, Midland, MI), which had been slit along its length. The tubing was allowed to close around the vessel and was anchored to adjacent muscle fascia with a 10/0 nylon suture (Davis & Geck, St. Louis, MO). One end was sealed with bone wax (Ethicon, Somerville, NJ), taking care not to occlude the emerging vessels, and the chamber was filled with growth factor reduced Matrigel (BD Biosciences, Bedford, MA) containing 1 mg/ mL of human recombinant bFGF (Sigma-Aldrich, Sydney, Australia) and 80 U/mL of unfractionated sodium heparin (APP, Schaumburg, IL). The steps to complete the chamber insertion were then varied from this point to give 3 different chamber configurations (Fig. 2) and a no-chamber control. There was a minimum of 5 animals in each group. In group 1 the second chamber end was also sealed with wax, except where the vascular pedicle exited the chamber, forming a completely sealed chamber. In group 2 the chamber was partially sealed with a wax plug with a 1-mm defect forming an ''open'' chamber. This opening abutted the surrounding epigastric fat pad, providing some contact with adipose tissue. Group 3 was identical to group 1 except that a piece of autologous adipose tissue from the wound bed (epididymal fat pad) was inserted into the chamber as a free graft before sealing, as in group 1 (Fig. 1B) . Two different amounts of fat were inserted: in group 3A, 2-5 mg was used (approximately 4-10% of the chamber volume), and in group 3B, 1 mg was used (mean weight, 1.03 mg AE 0.05 mg [SE] , approximately 2% of the chamber volume). In group 4, 300 mL of the same Matrigel mixture as used in the chamber groups was injected subcutaneously in the flank of the animal as a no-chamber control. The skin was closed with 9-mm Auto clips (Becton Dickinson, Sparks, MD).
The St. Vincent's Hospital institutional ethics committee approved all experiments in advance, and animal management complied with the Australian Code of Practice for the care and use of animals for scientific purposes.
Chamber removal and assessment
All animals were anesthetized without recovery at 6 weeks after chamber insertion, and the chambers were exposed surgically (Fig. 1C) . Vessel patency within the chambers was assessed macroscopically by looking for bleeding from the cut ends of the pedicle as it exited either end of the chamber. Contents of the chambers and subcutaneous plugs were removed and weighed, and the volume was determined by weighing the tissue while suspending it in a 0.9% sodium chloride solution (normal saline) at room temperature. 15 Tissue was routinely fixed in 10% neutral buffered formalin (Australian Biostain, Traralgon, Australia) and then embedded in paraffin. Serial histologic sections were stained routinely with hematoxylin and eosin and Masson's trichrome. The percentages of adipose tissue, residual Matrigel, fibrous granulation tissue, and vessels were determined by point-counting every 20th 5-mm section of each specimen by using digital video imaging ( JVC, TK C1480E) and an automated, systematic point-counting system (CAST system, Olympus, Albertslund, Denmark). Only living adipose tissue was counted; any nonviable fat, including graft remnants where seen, was not included in the count. Nonviable fat was distinguished from viable fat morphologically because it displays decreased intensity of staining, loss of nucleus, breakdown of cell membrane integrity, interstitial mononuclear cell infiltration, and formation of lipid cysts. Lipid cysts have a typical appearance of a space surrounded by a cyst wall containing multiple fibroblastoid cells with or without an inflammatory infiltrate.
It was not possible to distinguish between engrafted and newly produced fat in all specimens; therefore, percentage and volume of total adipose tissue were determined and compared with the volume of adipose tissue at insertion. Vessels were identified morphologically by their typical endothelial lining and by the presence of erythrocytes within their lumen. Results from such vessel counting have correlated well with point-counting of vessels labeled by using methods, such as lectin staining or India ink perfusion, applied in previous studies (results not shown). The proportion of each tissue type was then multiplied by the total volume of the chamber specimens to determine the volume of each tissue. Shrinkage from histologic processing was assumed to be constant across the 4 tissue types.
Statistical analysis
Mean tissue percentages and volumes were compared for statistical significance by using 1-way analysis of variance with post hoc analysis, with Dunnett's test as appropriate (GraphPad Prism Software, San Diego, CA). Statistical significance was set at p < 0.05.
RESULTS
Macroscopic appearance and vessel patency
The vessel patency rate of all chambers was over 90% and independent of chamber type. Those chambers in which the vascular pedicle had thrombosed were excluded from the study; however, no tissue grew in these chambers regardless of experimental group. Comparison of the specimens from the different groups, using transillumination and low magnification (Â12.5), showed 2 distinct patterns. Vascularization of Matrigel occurred from the vascular pedicle and extended to the periphery of the specimen, spreading out over the surface of the specimen in all cases (Fig. 1D) . Where fat had been left in contact with Matrigel, the specimens were opaque. Because Matrigel is transparent, opacity signified tissue/adipogenic replacement.
Histology
The same patterns of neovascularization as seen macroscopically were observed microscopically in all chamber groups, with new vessels branching from the main pedicle and extending through Matrigel to the periphery of the specimen (Fig. 3) . Most specimens had a fine fibrous capsule containing additional vessels. Fundamental differences were evident in the relative proportions of Matrigel and adipose tissue, and the distribution of these, in the different chamber configurations.
Sealed-chamber group. There was the same new vessel growth as seen in the other groups, and fibroblastoid cells, but few adipocytes were evenly distributed within the Matrigel (Fig. 3A) . Any adipocytes seen were usually close to the vascular pedicle and may be due to residual adipose tissue left on the vascular pedicle at chamber insertion.
Autograft chamber group. These showed adipocytes evenly distributed throughout the Matrigel (Fig. 3C and D) . Occasionally, small clusters of lipid cysts with typical multicellular, dense connective tissue cyst walls, with or without a surrounding inflammatory infiltrate, were present at the site of the original autograft. Adipogenesis within the 1-mg autograft chamber group showed 2 patterns. Approximately 60% of chambers showed good adipogenesis with the chamber specimens being indistinguishable from the 2-to 5-mg autograft chamber specimens. The remainder showed little or no adipogenesis despite the autograft remnants being visible, similar to the sealed-chamber specimens without an autograft.
Open-chamber group. There was marked adipogenesis within Matrigel in proximity to the open end of the chamber, and little or no adipogenesis seen at the opposite end of the chamber, where the chamber was completely sealed (Fig. 3B) .
Matrigel plug group. Subcutaneous injection of 300 mL of growth factor reduced Matrigel, together with 1 mg/mL of bFGF (Fig. 4) and heparin, resulted in angiogenic invasion of the plug and almost complete replacement by fat by 6 weeks, similar to that reported by Kawaguchi et al. (Fig. 5) . The difference in the percentage of adipose tissue between chamber groups was maximal and most consistent when a 2-to 5-mg autograft was included in the chamber ( p < 0.01 compared with sealed chamber). The 1-mg autograft group showed greater variability in percentage of adipose tissue, with most specimens having a percentage of adipose tissue similar to that of the 2-to 5-mg autograft group and others having very little adipogenesis. Because of this variability in response, no statistically significant difference in the mean adipose tissue percentage or volume was detected when we compared the 1-mg autograft group to the sealed-chamber specimens. Sealed chambers, with minimal or no access to adipose tissue, contained the least adipose tissue (<5%). Open chambers with intermediate access to preexisting adipose tissue developed intermediate amounts of adipose tissue, but this was not statistically significant when compared with the sealed-chamber specimens.
Vessels extended from the vascular pedicle to the periphery of the specimens in all groups. Neovascularization was similar across all chamber configurations, making up 10% of the chamber volume.
Granulation tissue was also measured. This was predominantly found at entrance and exit points for the pedicle and around the periphery of the specimen, where it formed a fine fibrous capsule. The volume of fibrous tissue produced did not differ between the groups (approximately 20-25% of the chamber volume in each case).
A significant residual volume of Matrigel was still evident at 6 weeks, although this was less in the specimens in which significant adipose tissue had formed ( p < 0.01 when comparing the sealed-chamber and 2-to 5-mg autograft groups).
DISCUSSION
The development of an injectable substance for human use that induces its own replacement by the de novo growth of adipose tissue would be of great benefit to many patients across multiple medical specialties. Such inductive adipogenesis has the benefit that it does not require the addition of stem cells harvested from the patient. Matrigel is a murine prototype of such a substance. When injected subcutaneously in mice, it induces angiogenesis followed by adipogenesis until its volume is replaced by adipose tissue. Matrigel is derived from a sarcoma in mice and therefore cannot be used for tissue engineering in humans. 12 It is hoped that a better understanding of the mechanism by which adipogenesis occurs within Matrigel will facilitate the development of an analog suitable for human use.
The mechanism whereby Matrigel induces de novo adipogenesis remains uncertain. Previous research has focussed on the role of Matrigel when combined with bFGF in promoting angiogenesis, which, in turn, appears to support adipogenesis, possibly via recruitment of precursors from the surrounding tissues. 13 The potential role of angiogenesis in facilitating adipose tissue production has been studied in vitro by the co-culture of endothelial cells, adipocytes, and preadipocytes in various combinations, [16] [17] [18] but to date it has not been possible to isolate each of these components in vivo.
In a simple mouse model of tissue engineering we have examined the interaction between existing vessels and tissue in the inductive formation of new adipose tissue within Matrigel. We have shown that Matrigel with bFGF, when excluded from an adipose tissue source, will become vascularized but will not develop significant adipose tissue. When a free graft of adipose tissue is added to the chamber, or when one end of the chamber is open for access to surrounding fat, new adipose tissue forms within the Matrigel adjacent to this preexisting tissue. The degree of volume change in the autograft specimens could not be explained by adipocyte hypertrophy because adipocyte size in the chamber specimens at harvest was similar to the graft adipocyte size at insertion.
It is evident in our in vivo model that a suitable matrix, a patent vascular pedicle, and bFGF are not sufficient by themselves to generate fat. A tissue source in addition to a vascular pedicle is essential for the inductive growth of new adipose tissue. Such definition has not been possible in subcutaneous models but is afforded by the isolative nature of our sealed chamber. We found that adipose tissue appeared to grow best in close proximity to an existing or grafted fat source. Toriyama et al., 13 using the subcutaneous Matrigel model in which fat abuts the Matrigel plug, observed by electron microscopy that multiple layers of cells at the periphery differentiate into adipocytes or endothelial cells, and progressively invade the Matrigel. They observed that the new fat derives at the point where existing fat contacts the Matrigel, consistent with our observations. The absence of significant adipogenesis in our sealed-chamber model supports the assertion that access to surrounding tissues is important for inductive adipogenesis within Matrigel.
No statistically significant differences were detected in the vascularity of the chamber specimens across the different chamber configurations. This finding suggests that angiogenesis in Matrigel only requires access to an existing vasculature or that the influence of existing tissue (e.g., the autograft) on angiogenesis was negligible. The development of neovascularization throughout Matrigel within sealed chambers did not itself induce an adipogenic response. The few adipocytes seen in the sealed-chamber specimens may be residual adipocytes left on the vascular pedicle at chamber insertion. Alternatively, they may represent adipogenesis produced by recruitment of mesenchymal stem cells via the circulation in the absence of preexisting tissue. Unlike neovascularization, neoadipogenesis in Matrigel / bFGF requires more than access to an existing vasculature. The factor or factors provided by existing fat that promote neoadipogenesis are not yet determined. Mesenchymal stem cells have been identified in adipose tissue, 19 and thus the adipose tissue in or near our chambers may be acting as a source of preadipocytes. Stem cells make up only a very small percentage of the cells within each tissue, 20 and this is consistent with the variable adipogenic response found with inclusion of a 1-mg autograft within the chamber when compared with the more consistent adipogenesis seen with 2-to 5-mg autografts. If stem cells were the major contribution of the preexisting adipose tissue (either host or grafted) in our system, this would suggest that angiogenesis in a sealed chamber leads to minimal or no recruitment of mesenchymal stem cells via the circulation. Also, recent studies in our laboratory using human adipose tissue xenografts show that the new adipose tissue is predominantly murine, suggesting that the graft is inductive of preadipocyte recruitment rather than providing stem cells directly. 21 Other factors, such as the release of extracellular matrix components, 15, 16 paracrine factors, 17 or chemokines from the autograft, may also play a role in fostering the neoadipogenesis by stimulating adipogenesis from precursors recruited from the circulation. Experiments designed to isolate each of these pathways to examine their role in tissueinduced adipogenesis are in progress.
Increasing evidence suggests close interactions between angiogenesis and adipogenesis. The precise nature of these interactions remains unclear. A paracrine-based interaction between endothelial cells and preadipocytes has been shown in vivo to involve vascular endothelial growth factor (VEGF) and VEGF receptor-2 signaling within the endothelial cells. 22 Aoki et al. 18 showed that co-culture of endothelial cells and mature adipocytes (in vitro) actively promotes immature preadipocyte development. These preadipocytes appeared predominantly at the adhesion sites between the endothelial and mature adipocytes. This effect was not reproduced by endothelial cell-conditioned media or by certain endothelial cell-produced cytokines, suggesting that endothelial cells are involved in the enlargement mechanism of adipose tissue mass through their direct adhesion to mature adipocytes. Antiangiogenesic agents have been shown to cause vascular remodeling and reduce adipose tissue mass in murine models of obesity in a dosedependent fashion, confirming a regulation of adipose tissue by its vasculature. 23 Hypoxia has been shown to inhibit adipogenesis via the hypoxia-inducible factor-1-regulated gene DEC1/Stra13, which causes repression of peroxisome proliferator-activated receptor-g. 24 These findings are consistent with our observation that no fat formed when the epigastric vessel pedicle was thrombosed, but the absence of adipogenesis in the sealed chamber, despite considerable angiogenesis, indicates that angiogenesis is necessary but not sufficient in the Matrigel/bFGF environment to cause neoadipogenesis.
The current clinical strategies for the use of adipose tissue in surgical reconstruction and augmentation rely on engraftment and revascularization of the adipose tissue graft, rather than on de novo adipogenesis. Our data indicate an important inductive role of preexisting adipose tissue, whether vital or isolated, in generating new adipose tissue with Matrigel with bFGF. Greater understanding of the mechanism of adipogenesis in response to Matrigel in mice takes us closer to developing a human equivalent for human use and has important implications for chamber design for the production of larger volumes of tissue. National Health and Medical Research Council and National Australia Bank is gratefully acknowledged.
